Found 24 articles
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Im...
INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose
Intrommune Therapeutics today announced that its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy has been amended to allow determination of the Maximum Tolerated Dose (MTD).
Prota Therapeutics Achieves Peanut Allergy Treatment Milestone: Groundbreaking Clinical Trial Data Demonstrates Clinical Remission of Peanut Allergy in Paediatric Patients
Prota Therapeutics, an Australian biotechnology company focused on the development of novel oral immunotherapy treatments, has achieved a significant milestone in the treatment of peanut allergy in children.
Intrommune Therapeutics, Inc. today announced an initial update from its ongoing Phase 1 OMEGA Trial of INT301 in patients with peanut allergy.
Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut
Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut.
Angany Inc., announces that it has entered into a partnering agreement with Dr. Wayne Shreffler, MD, PhD, Chief, Division of Pediatric Allergy & Immunology and Director of the Food Allergy Center at Massachusetts General Hospital and MassGeneral Hospital for Children, for a comprehensive series of preclinical studies of Angany's peanut allergy biologic candidate BP/AH-01.
Aimmune Therapeutics to Present New Data at ACAAI on the Real-World Burden of Peanut Allergy and Early Physician Experience with PALFORZIA® in Clinical Practice in the U.S.
Aimmune Therapeutics to Present New Data at ACAAI on the Real-World Burden of Peanut Allergy and Early Physician Experience with PALFORZIA ® in Clinical Practice in the U.S.
FDA Accepts Investigational New Drug Application for Peanut Allergy Candidate Developed by COUR Pharmaceuticals
First-of-its-kind study will evaluate safety and efficacy of CNP-201, a nanoparticle containing peanut protein, in eliminating allergic responses
Intrommune Therapeutics, Inc. announced the appointment of Stuart Loesch as its new Chief Commercial Officer.
Advisory - One lot of pms-PROGESTERONE 100 mg capsules recalled because it may pose serious risks to individuals with severe peanut allergies
Pharmascience Inc. is recalling one lot of pms-PROGESTERONE 100 mg capsules because the bottles may contain Akorn 100 mg progesterone gelatin capsules in addition to or instead of the intended pms-PROGESTERONE 100 mg gelatin capsules.
Aimmune’s PALISADE-ARC004 Longitudinal Study Showed PALFORZIA® Safety and Efficacy Increased Over Time in Patients with Peanut Allergy
Aimmune’s PALISADE-ARC004 Longitudinal Study Showed PALFORZIA ® Safety and Efficacy Increased Over Time in Patients with Peanut Allergy
AllerGenis announced the publication of a peer-reviewed study entitled, "Accurate and Reproducible Diagnosis of Peanut Allergy Using Epitope Mapping." Conducted by leading global experts in pediatric allergy and immunology from the Icahn School of Medicine at Mount Sinai, Stanford University and Kings College, the study found the AllerGenis peanut diagnostic blood test demonstrates accuracy significantly and statistically superior to all other established diagnostic tests.
Ukko Secures $40 Million in Series B Funding Led by Leaps by Bayer to Overcome Food Allergies and Sensitivities
Top industry leaders and venture firms unite behind Ukko's efforts to eliminate the world's most prevalent food allergies and sensitivities, including peanuts and gluten
Intrommune to Participate in BIO @ JPM During “J.P. Morgan Week 2021”Virtual Bio-Partnering Platform Connects Biotech Leaders with Investors; Partners
Intrommune Therapeutics , a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, will participate in BIO’s one-on-one virtual partnering meeting during the 39 th annual J.P. Morgan Healthcare Conference taking place January 11 – 14, 2021. The BIO One-on-One Partnering @ JPM platform enables partners and investors to schedule virtual video meetings with Intrommune executives. To
DBV Technologies aims to fill the peanut allergy treatment gap, especially for highly allergic children, with their low dose epicutaneous immunotherapy (EPIT) patch Viaskin™ Peanut.
In its CRL, the FDA identified concerns regarding the impact of patch-site adhesion on efficacy and indicated the need for patch modifications.
AllerGenis Begins Testing Patient Samples for Peanut Allergy Using Proprietary Epitope Mapping Technology
AllerGenis LLC, a data-driven precision diagnostics company focused on food allergies, today announced the onset of operations at its Hatfield facility to test patient samples using its VeriMAP TM Peanut Diagnostic, a diagnostic solution for patients with peanut allergies. AllerGenis received full certification under Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform its high complexity clinical l
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut Allergy
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut Allergy — After Two Years of Daily Treatment, More Than 80% of Patients Were Successfully Desensitized to 2000 mg Peanut Protein or Equivalent of About 14 Peanut Kernels— — Majority of Patients Treated Daily Also Reported Lower Rates of Adverse Events and Showed Higher Rates of Desensitization Compared to Non-Daily Dosing Groups —
Aimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA™, the First Treatment for Peanut Allergy
Aimmune Therapeutics, Inc. today announced that the first patients in the United States are being treated with PALFORZIA™ [Peanut ( Arachis hypogaea ) Allergen Powder-dnfp], the first approved treatment for peanut allergy. Following the release of the medication lots by the U.S. Food an
DBV announced positive topline results from its Phase III PEPITES trial evaluating the long-term efficacy and safety of investigational Viaskin Peanut in peanut-allergic children aged 4 to 11 years.